Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Obatoclax

Drug Profile

Obatoclax

Alternative Names: CEP-41601; GX 15-070; GX15-070MS; Obatoclax mesylate

Latest Information Update: 07 Mar 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gemin X Biotechnologies
  • Class Antineoplastics; Pyrroles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Autophagy stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Chronic lymphocytic leukaemia; Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Aplastic anaemia; Chronic lymphocytic leukaemia; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Non-small cell lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Small cell lung cancer; Systemic mastocytosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Dec 2013 Discontinued - Phase-I for Multiple myeloma in USA (IV)
  • 31 Dec 2013 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia in USA and Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top